Back to results
US 2017/0281566 A1Published application
Combinations of lsd1 inhibitors for the treatment of hematological malignancies
AssigneeHoffmann-La Roche Inc.
InventorsFilippo CICERI, Serena LUNARDI, Tamara MAES, Cristina MASCARÓ CRUSAT, Iñigo TIRAPU FERNÁNDEZ DE LA CUESTA
Life of this patent
Estimating the term…
Abstract
The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
Claims45
A combination comprising a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents selected from a retinoic acid analogue, a nucleoside analogue, a DOT1L inhibitor, a HDAC inhibitor, a demethylating agent, an FLT3 inhibitor, a BCL2 inhibitor, an MDM2 inhibitor, a c-KIT inhibitor, a BET inhibitor, an anthracycline, arsenic trioxide, hydroxyurea and pharmaceutically acceptable salts thereof.
30-32. (canceled)
35-36. (canceled)
(canceled)
Dependencies are inferred from the claim text.